A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF Alpha Inhibitor.

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF Alpha Inhibitor.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Mesoblast
  • Most Recent Events

    • 17 Jun 2017 Results assessing safety, tolerability and the clinical efficacy of Mesenchymal Precursor Cells therapy in Rheumatoid Arthritis patients, presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 10 Jun 2017 Biomarkers information updated
    • 21 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top